AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 44.95 USD 2.63%
Market Cap: 1.2B USD

AnaptysBio Inc
Cash from Investing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

AnaptysBio Inc
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
Cash from Investing Activities
$125.1m
CAGR 3-Years
N/A
CAGR 5-Years
6%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Investing Activities
-$7.1B
CAGR 3-Years
-75%
CAGR 5-Years
28%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Investing Activities
-$3.2B
CAGR 3-Years
-10%
CAGR 5-Years
9%
CAGR 10-Years
11%
Amgen Inc
NASDAQ:AMGN
Cash from Investing Activities
-$1.7B
CAGR 3-Years
16%
CAGR 5-Years
30%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Investing Activities
-$1.5B
CAGR 3-Years
-33%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Investing Activities
-$498.8m
CAGR 3-Years
50%
CAGR 5-Years
N/A
CAGR 10-Years
4%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
69.95 USD
Undervaluation 36%
Intrinsic Value
Price

See Also

What is AnaptysBio Inc's Cash from Investing Activities?
Cash from Investing Activities
125.1m USD

Based on the financial report for Sep 30, 2025, AnaptysBio Inc's Cash from Investing Activities amounts to 125.1m USD.

What is AnaptysBio Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
6%

Over the last year, the Cash from Investing Activities growth was -28%.

Back to Top